MEA Vascular Stent Market

MEA Vascular Stent Market Size (2022 to 2027)

The size of the Vascular Stent Market in the Middle East & Africa has been estimated at USD 1.80 billion in 2022. It is projected to be growing at a CAGR of 8.9% and worth USD 2.75 billion by 2027.

A stent is an expandable and tiny mesh made of metals or polymers. An implanted stent stays in the artery permanently, although a blocked stent can be removed by an angiography procedure.

The main purpose of a vascular stent is to provide support in keeping the clogged artery open which leads to a better and increased blood flow to the heart. The unclogged arteries and increased blood flow substantively reduce the probability of a heart attack.

The growth of the Middle East and Africa Vascular Stent Market is driven by the increasing use of vascular stents for cardiovascular diseases. This is further supplemented by the increasing preference for stents over other outdated methods which were relatively more invasive. The rising elderly populace in the Middle-East and Africa with the consequently increasing incidence of CVDs is also a major sponsor of market growth in the region.

The restraints faced by the market include the stern regulation guidelines by governmental bodies and a rising number of cases of product failure and recalls.

This research report on the Middle East and Africa Vascular Stent Market has been segmented and sub-segmented into the following categories.

By Product: 

• Peripheral Stents
• Coronary Stents
• EVAR Stent Grafts

By Type: 

• Bare-Metal Stents
• Drug-Eluting Stents
• Bioabsorbable Stents

By Mode of Delivery: 

• Self-Expanding Stents
• Balloon Expanding Stents

By Material: 

• Metal
• Polymer

By End User: 

• Hospitals
• Research Institutes

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Companies that have presence in the Middle East & Africa Vascular Stent Market profiled in the report are Medtronic, plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), W. L. Gore and Associates (U.S.), C. R. Bard (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Translumina GmbH (Germany), and JOTEC GmbH (Germany).